Seminars in Hematology
Volume 44, Issue 3 , Pages 203-211 , July 2007

Hematopoietic Growth Factors Including Keratinocyte Growth Factor in Allogeneic and Autologous Stem Cell Transplantation

  • Ruth Seggewiss
    • ,
  • Hermann Einsele

      Affiliations

    • Corresponding Author InformationAddress correspondence to Hermann Einsele, MD, Department of Internal Medicine II, Julius-Maximilians-University, Josef-Schneider-Strasse 2, 97080 Würzburg, Germany.

References 

  1. McGlave PB, Shu XO, Wen W, Anasetti C, Nademanee A, Champlin R, et al. Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 years’ experience of the national marrow donor program. Blood. 2000;95:2219–2225
  2. Small TN, Avigan D, Dupont B, Smith K, Black P, Heller G, et al. Immune reconstitution following T-cell depleted bone marrow transplantation: Effect of age and posttransplant graft rejection prophylaxis. Biol Blood Marrow Transplant. 1997;3:65–75
  3. Wynn RF, Cross MA, Hatton C, Will AM, Lashford LS, Dexter TM, et al. Accelerated telomere shortening in young recipients of allogeneic bone-marrow transplants. Lancet. 1998;351:178–181
  4. Burgess AW, Metcalf D. The nature and action of granulocyte-macrophage colony stimulating factors. Blood. 1980;56:947–958
  5. Nicola NA, Metcalf D, Matsumoto M, Johnson GR. Purification of a factor inducing differentiation in murine myelomonocytic leukemia cells (Identification as granulocyte colony-stimulating factor). J Biol Chem. 1983;258:9017–9023
  6. Lieschke GJ, Stanley E, Grail D, Hodgson G, Sinickas V, Gall JA, et al. Mice lacking both macrophage- and granulocyte-macrophage colony-stimulating factor have macrophages and coexistent osteopetrosis and severe lung disease. Blood. 1994;84:27–35
  7. Lieschke GJ, Grail D, Hodgson G, Metcalf D, Stanley E, Cheers C, et al. Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization. Blood. 1994;84:1737–1746
  8. Liu F, Wu HY, Wesselschmidt R, Kornaga T, Link DC. Impaired production and increased apoptosis of neutrophils in granulocyte colony-stimulating factor receptor-deficient mice. Immunity. 1996;5:491–501
  9. Seymour JF, Lieschke GJ, Grail D, Quilici C, Hodgson G, Dunn AR. Mice lacking both granulocyte colony-stimulating factor (CSF) and granulocyte-macrophage CSF have impaired reproductive capacity, perturbed neonatal granulopoiesis, lung disease, amyloidosis, and reduced long-term survival. Blood. 1997;90:3037–3049
  10. Basu S, Hodgson G, Zhang HH, Katz M, Quilici C, Dunn AR. ”Emergency” granulopoiesis in G-CSF-deficient mice in response to Candida albicans infection. Blood. 2000;95:3725–3733
  11. Kawakami M, Tsutsumi H, Kumakawa T, Abe H, Hirai M, Kurosawa S, et al. Levels of serum granulocyte colony-stimulating factor in patients with infections. Blood. 1990;76:1962–1964
  12. Safdar A. Strategies to enhance immune function in hematopoietic transplantation recipients who have fungal infections. Bone Marrow Transplant. 2006;38:327–337
  13. Klumpp TR, Goldberg SL, Mangan KF. Effect of granulocyte colony-stimulating factor on the rate of neutrophil engraftment following peripheral-blood stem-cell transplantation. J Clin Oncol. 1995;13:2144
  14. Dekker A, Bulley S, Beyene J, Dupuis LL, Doyle JJ, Sung L. Meta-analysis of randomized controlled trials of prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor after autologous and allogeneic stem cell transplantation. J Clin Oncol. 2006;24:5207–5215
  15. Ho VT, Mirza NQ, Junco Dd D, Okamura T, Przepiorka D. The effect of hematopoietic growth factors on the risk of graft-vs-host disease after allogeneic hematopoietic stem cell transplantation: A meta-analysis. Bone Marrow Transplant. 2003;32:771–775
  16. Bradstock KF. The use of hematopoietic growth factors in the treatment of acute leukemia. Curr Pharm Des. 2002;8:343–355
  17. Lowenberg B. Minimal residual disease in chronic myeloid leukemia. N Engl J Med. 2003;349:1399–1401
  18. Amadori S, Suciu S, Jehn U, Stasi R, Thomas X, Marie JP, et al. Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: Final results of AML-13, a randomized phase-3 study. Blood. 2005;106:27–34
  19. Sakai M, Ohashi K, Kobayashi T, Yamashita T, Akiyama H, Sakamaki H, et al. Treatment with granulocyte colony-stimulating factor after allogeneic transplantation increases the risk of hepatic veno-occlusive disease and death: A retrospective analysis of 440 cases at a single center. 2005;American Society of Hematology Annual Meeting, Atlanta, GA
  20. Pan L, Delmonte J, Jalonen CK, Ferrara JL, et al. Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease. Blood. 1995;86:4422–4429
  21. Mielcarek M, Martin PJ, Torok-Storb P. Suppression of alloantigen-induced T-cell proliferation by CD14+ cells derived from granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells. Blood. 1997;89:1629–1634
  22. Franzke A, Piao W, Lauber J, Gatzlaff P, Konecke C, Hansen W, et al. G-CSF as immune regulator in T cells expressing the G-CSF receptor: Implications for transplantation and autoimmune diseases. Blood. 2003;102:734–739
  23. Arpinati M, Green CL, Heimfeld S, Heuser JE, Anasetti C. Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells. Blood. 2000;95:2484–2490
  24. Rutella S, Bonanno G, Pierelli L, Mariotti A, Capoluongo E, Contemi AM, et al. Granulocyte colony-stimulating factor promotes the generation of regulatory DC through induction of IL-10 and IFN-alpha. Eur J Immunol. 2004;34:1291–1302
  25. Morris ES, MacDonald KP, Rowe V, Johnson DH, Banovic T, Clouston AD, et al. Donor treatment with pegylated G-CSF augments the generation of IL-10-producing regulatory T cells and promotes transplantation tolerance. Blood. 2004;103:3573–3581
  26. Bishop MR, Tarantolo SR, Geller RB, Lynch JC, Bierman PJ, Pavletic ZS, et al. A randomized, double-blind trial of filgrastim (granulocyte colony-stimulating factor) versus placebo following allogeneic blood stem cell transplantation. Blood. 2000;96:80–85
  27. Remberger M, Naseh N, Aschan J, Barkholt L, LeBlanc K, Svennberg P, et al. G-CSF given after haematopoietic stem cell transplantation using HLA-identical sibling donors is associated to a higher incidence of acute GVHD II-IV. Bone Marrow Transplant. 2003;32:217–223
  28. Ringden O, Labopin M, Gorin NC, Le Blanc K, Rocha V, Gluckman E, et al. Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: A study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2004;22:416–423
  29. To LB, Bashford J, Durrant S, MacMillan J, Schwarer AP, Prince HM, et al. Successful mobilization of peripheral blood stem cells after addition of ancestim (stem cell factor) in patients who had failed a prior mobilization with filgrastim (granulocyte colony-stimulating factor) alone or with chemotherapy plus filgrastim. Bone Marrow Transplant. 2003;31:371–378
  30. Prosper F, Sola C, Hornedo J, Arbona C, Menendez P, Orfao A, et al. Mobilization of peripheral blood progenitor cells with a combination of cyclophosphamide, r-metHuSCF and filgrastim in patients with breast cancer previously treated with chemotherapy. Leukemia. 2003;17:437–441
  31. Wadhwa PD, Lazarus HM, Koc ON, Jaroscak J, Woo D, Stevens CE, et al. Hematopoietic recovery after unrelated umbilical cord-blood allogeneic transplantation in adults treated with in vivo stem cell factor (R-MetHuSCF) and filgrastim administration. Leuk Res. 2003;27:215–220
  32. Miller CB, Jones RJ, Zahurak ML, Piantadosi S, Burns WH, Santos GW, et al. Impaired erythropoietin response to anemia after bone marrow transplantation. Blood. 1992;80:2677–2682
  33. Fox CP, Pacey S, Das-Gupta EP, Russell NH, Byrne JL. Low dose erythropoietin is effective in reducing transfusion requirements following allogeneic HSCT. Transfus Med. 2005;15:475–480
  34. Fujimori Y, Kanamaru A, Saheki K, Mori A, Takatsuka H, Wada W, et al. Recombinant human erythropoietin for late-onset anemia after allogeneic bone marrow transplantation. Int J Hematol. 1998;67:131–136
  35. Baron F, Sautois B, Baudoux E, Matus G, Fillet G, Beguin Y. Optimization of recombinant human erythropoietin therapy after allogeneic hematopoietic stem cell transplantation. Exp Hematol. 2002;30:546–554
  36. Biggs JC, Atkinson KA, Booker V, Concannon A, Dart GW, Dodds A, et al. The Australian Bone Marrow Transplant Study Group Prospective randomised double-blind trial of the in vivo use of recombinant human erythropoietin in bone marrow transplantation from HLA-identical sibling donors. Bone Marrow Transplant. 1995;15:129–134
  37. Pierelli L, Scambia G, Menichella G, d’Onofrio G, Salerno G, Panici PB, et al. The combination of erythropoietin and granulocyte colony-stimulating factor increases the rate of haemopoietic recovery with clinical benefit after peripheral blood progenitor cell transplantation. Br J Haematol. 1996;92:287–294
  38. Vannucchi AM, Bosi A, Linari S, Guidi S, Longo G, Lombardini L, et al. High doses of recombinant human erythropoietin fail to accelerate platelet reconstitution in allogeneic bone marrow transplantation (Results of a pilot study). Haematologica. 1997;82:53–56
  39. Deeren DH, Zachee P, Malbrain ML. Granulocyte colony-stimulating factor-induced capillary leak syndrome confirmed by extravascular lung water measurements. Ann Hematol. 2005;84:89–94
  40. Stanworth SJ, Hyde C, Brunskill S, Murphy MF. Platelet transfusion prophylaxis for patients with haematological malignancies: Where to now?. Br J Haematol. 2005;131:588–595
  41. Wagemaker G, Neelis KJ, Hartong SCC, Wognum AW, Thomas GR, Fielder PJ, et al. The efficacy of recombinant TPO in murine and nonhuman primate models for myelosuppression and stem cell transplantation. Stem Cells. 1998;16(suppl 2):127–141
  42. Miyazaki H, Kato T. Thrombopoietin: Biology and clinical potentials. Int J Hematol. 1999;70:216–225
  43. Archimbaud E, Ottmann OG, Yin JA, Lechner K, Dombret H, Sanz MA, et al. A randomized, double-blind, placebo-controlled study with pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) as an adjunct to chemotherapy for adults with de novo acute myeloid leukemia. Blood. 1999;94:3694–3701
  44. Schiffer CA, Miller K, Larson RA, Amrein PC, Antin JH, Zani VJ, et al. A double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia. Blood. 2000;95:2530–2535
  45. Nash RA, Kurzrock R, DiPersio J, Vose J, Linker C, Maharaj D, et al. A phase I trial of recombinant human thrombopoietin in patients with delayed platelet recovery after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2000;6:25–34
  46. Kuter DJ, Begley CG. Recombinant human thrombopoietin: Basic biology and evaluation of clinical studies. Blood. 2002;100:3457–3469
  47. Kuter DJ. New thrombopoietic growth factors. Blood. 2007;prepublished online, DOI 10.1182/blood-2006-10-019315
  48. Hamon MD, Prentice HG, Gottlieb DJ, Macdonald ID, Cunningham JM, Smith OP, et al. Immunotherapy with interleukin 2 after ABMT in AML. Bone Marrow Transplant. 1993;11:399–401
  49. Soiffer RJ, Murray C, Cochran K, Cameron C, Wang E, Schow PW, et al. Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation. Blood. 1992;79:517–526
  50. Perillo A, Pierelli L, Battaglia A, Salerno MG, Rutella S, Cortesi E, et al. Administration of low-dose interleukin-2 plus G-CSF/EPO early after autologous PBSC transplantation: Effects on immune recovery and NK activity in a prospective study in women with breast and ovarian cancer. Bone Marrow Transplant. 2002;30:571–578
  51. Pierelli L, Bonanno G, Rutella S, Marone M, Scambia G, Leone G. CD105 (endoglin) expression on hematopoietic stem/progenitor cells. Leuk Lymphoma. 2001;42:1195–1206
  52. Slavin S, Naparstek E, Nagler A, Ackerstein A, Samuel S, Kapelushnik J, et al. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood. 1996;87:2195–2204
  53. Nadal E, Fowler A, Kanfer E, Apperley J, Goldman J, Dazzi F. Adjuvant interleukin-2 therapy for patients refractory to donor lymphocyte infusions. Exp Hematol. 2004;32:218–223
  54. Mackall CL, Fry TJ, Bare C, Morgan P, Galbraith A, Gress RE. IL-7 increases both thymic-dependent and thymic-independent T-cell regeneration after bone marrow transplantation. Blood. 2001;97:1491–1497
  55. Fry TJ, Connick E, Falloon J, Lederman MM, Liewehr DJ, Spritzler J, et al. A potential role for interleukin-7 in T-cell homeostasis. Blood. 2001;97:2983–2990
  56. Fry TJ, Christensen BL, Komschlies KL, Gress RE, Mackall CL. Interleukin-7 restores immunity in athymic T-cell-depleted hosts. Blood. 2001;97:1525–1533
  57. Bolotin E, Smogorzewska M, Smith S, Widmer M, Weinberg K. Enhancement of thymopoiesis after bone marrow transplant by in vivo interleukin-7. Blood. 1996;88:1887–1894
  58. Alpdogan O, Schmaltz C, Muriglan SJ, Kappel BJ, Perales MA, Rotolo JA, et al. Administration of interleukin-7 after allogeneic bone marrow transplantation improves immune reconstitution without aggravating graft-versus-host disease. Blood. 2001;98:2256–2265
  59. Alpdogan O, Muriglan SJ, Eng JM, Willis LM, Greenberg AS, Kappel BJ, et al. IL-7 enhances peripheral T cell reconstitution after allogeneic hematopoietic stem cell transplantation. J Clin Invest. 2003;112:1095–1107
  60. Sinha ML, Fry TJ, Fowler DH, Miller G, Mackall CL. Interleukin 7 worsens graft-versus-host disease. Blood. 2002;100:2642–2649
  61. Storek J, Gillespy T, Lu H, Joseph A, Dawson MA, Gough M, et al Interleukin-7 improves CD4 T-cell reconstitution after autologous CD34 cell transplantation in monkeys. Blood. 2003;101:4209–4218
  62. Cooper MA, Bush JE, Fehniger TA, VanDeusen JB, Waite RE, Liu Y, et al. In vivo evidence for a dependence on interleukin 15 for survival of natural killer cells. Blood. 2002;100:3633–3638
  63. Tan JT, Ernst B, Kieper WC, LeRoy E, Sprent J, Surh CD. Interleukin (IL)-15 and IL-7 jointly regulate homeostatic proliferation of memory phenotype CD8+ cells but are not required for memory phenotype CD4+ cells. J Exp Med. 2002;195:1523–1532
  64. Goldrath AW, Sivakumar PV, Glaccum M, Kennedy MK, Bevan MJ, Benoist C, et al. Cytokine requirements for acute and basal homeostatic proliferation of naive and memory CD8+ T cells. J Exp Med. 2002;195:1515–1522
  65. Alpdogan O, Eng JM, Muriglan SJ, Willis LM, Hubbard VM, Tjoe KH, et al. Interleukin-15 enhances immune reconstitution after allogeneic bone marrow transplantation. Blood. 2005;105:865–873
  66. Lin SJ, Cheng PJ, Hsiao SS. Effect of interleukin-15 on effector and regulatory function of anti-CD3/anti-CD28-stimulated CD4(+) T cells. Bone Marrow Transplant. 2006;37:881–887
  67. Spielberger R, Stiff P, Bensinger W, Gentile T, Weisdorf D, Kewalramani T, et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med. 2004;351:2590–2598
  68. Min D, Taylor PA, Panoskaltsis-Mortari A, Chung B, Danilenko DM, Farrell C, et al. Protection from thymic epithelial cell injury by keratinocyte growth factor: A new approach to improve thymic and peripheral T-cell reconstitution after bone marrow transplantation. Blood. 2002;99:4592–4600
  69. Farrell CL, Bready JV, Rex KL, Chen JN, DiPalma CR, Whitcomb KL, et al. Keratinocyte growth factor protects mice from chemotherapy and radiation-induced gastrointestinal injury and mortality. Cancer Res. 1998;58:933–939
  70. Ulich TR, Whitcomb L, Tang W, O’Conner Tressel P, Tarpley J, Yi ES, et al. Keratinocyte growth factor ameliorates cyclophosphamide-induced ulcerative hemorrhagic cystitis. Cancer Res. 1997;57:472–475
  71. Rossi S, Blazar BR, Farrell CL, Danilenko DM, Lacey DL, Weinberg KI, et al. Keratinocyte growth factor preserves normal thymopoiesis and thymic microenvironment during experimental graft-versus-host disease. Blood. 2002;100:682–691
  72. Seggewiss R, Lore K, Guenaga FJ, Pittaluga S, Mattapallil J, Chow CK, et al. Keratinocyte growth factor augments immune reconstitution after autologous hematopoietic progenitor cell transplantation in rhesus macaques. Blood. 2007;prepublished online, DOI 10.1182/blood-2006-12-065623
  73. Bruinsma M, van Soest PL, Leenen PJM, Lowenberg B, Cornelissen JJ, Braakman E, et al. Keratinocyte growth factor increases the CD4+Foxp3+ rgulatory T cell-pool by an early thymus-independent and a late thymus-dependent mechanism. 2006;American Society of Hematology Annual Meeting, Orlando, FL
  74. Blazar BR, Weisdorf DJ, Defor T, Goldman A, Braun T, Silver S, et al. Phase 1/2 randomized, placebo-control trial of palifermin to prevent graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). Blood. 2006;108:3216–3222
  75. Clark RA, Yamanaka K, Bai M, Dowgiert R, Kupper TS. Human skin cells support thymus-independent T cell development. J Clin Invest. 2005;115:3239–3249
  76. Heng TS, Goldberg GL, Gray DH, Sutherland JS, Chidgey AP, Boyd RL. Effects of castration on thymocyte development in two different models of thymic involution. J Immunol. 2005;175:2982–2993
  77. Sutherland JS, Goldberg GL, Hammett MV, Uldrich AP, Berzins SP, Heng TS, et al. Activation of thymic regeneration in mice and humans following androgen blockade. J Immunol. 2005;175:2741–2753
  78. Nakamura T, Nishizawa T, Hagiya M, Seki T, Shimonishi M, Sugimura A, et al. Molecular cloning and expression of human hepatocyte growth factor. Nature. 1989;342:440–443
  79. Kmiecik TE, Keller JR, Rosen E, Vande Woude GF. Hepatocyte growth factor is a synergistic factor for the growth of hematopoietic progenitor cells. Blood. 1992;80:2454–2457
  80. Kuroiwa T, Kakishita E, Hamano T, Kataoka Y, Seto Y, Iwata N, et al. Hepatocyte growth factor ameliorates acute graft-versus-host disease and promotes hematopoietic function. J Clin Invest. 2001;107:1365–1373
  81. Imado T, Iwasaki T, Kataoka Y, Kuroiwa T, Hara H, Fujimoto J, et al. Hepatocyte growth factor preserves graft-versus-leukemia effect and T-cell reconstitution after marrow transplantation. Blood. 2004;104:1542–1549
  82. Okamoto T, Takatsuka H, Fujimori Y, Wada H, Iwasaki T, Kakishita E. Increased hepatocyte growth factor in serum in acute graft-versus-host disease. Bone Marrow Transplant. 2001;28:197–200
  83. Pellegrini I, Lebrun JJ, Ali S, Kelly PA. Expression of prolactin and its receptor in human lymphoid cells. Mol Endocrinol. 1992;6:1023–1031
  84. Bellone G, Geuna M, Carbone A, Silvestri S, Foa R, Emanuelli G, et al. Regulatory action of prolactin on the in vitro growth of CD34+ve human hemopoietic progenitor cells. J Cell Physiol. 1995;163:221–231
  85. Gagnerault MC, Postel-Vinay MC, Dardenne M. Expression of growth hormone receptors in murine lymphoid cells analyzed by flow cytofluorometry. Endocrinology. 1996;137:1719–1726
  86. Sun R, Gault RA, Welniak LA, Tian ZG, Richards S, Murphy WJ. Immunologic and hematopoietic effects of recombinant human prolactin after syngeneic bone marrow transplantation in mice. Biol Blood Marrow Transplant. 2003;9:426–434
  87. Kooijman R, Malur A, Van Buul-Offers SC, Hooghe-Peters EL. Growth hormone expression in murine bone marrow cells is independent of the pituitary transcription factor Pit-1. Endocrinology. 1997;138:3949–3955
  88. Murphy WJ, Durum SK, Longo DL. Role of neuroendocrine hormones in murine T cell development (Growth hormone exerts thymopoietic effects in vivo). J Immunol. 1992;149:3851–3857
  89. Murphy WJ, Durum SK, Anver MR, Longo DL. Immunologic and hematologic effects of neuroendocrine hormones (Studies on DW/J dwarf mice). J Immunol. 1992;148:3799–3805
  90. Chen BJ, Cui X, Sempowski GD, Chao NL. Growth hormone accelerates immune recovery following allogeneic T-cell-depleted bone marrow transplantation in mice. Exp Hematol. 2003;31:953–958
  91. Knyszynski A, Adler-Kunin S, Globerson A. Effects of growth hormone on thymocyte development from progenitor cells in the bone marrow. Brain Behav Immun. 1992;6:327–340
  92. Welniak LA, Sun R, Murphy WJ. The role of growth hormone in T-cell development and reconstitution. J Leukoc Biol. 2002;71:381–387
  93. Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, et al. 2006 update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline. J Clin Oncol. 2006;24:3187–3205

PII: S0037-1963(07)00072-8

doi: 10.1053/j.seminhematol.2007.04.009

Seminars in Hematology
Volume 44, Issue 3 , Pages 203-211 , July 2007

Article Tools